10-Q 1 amgn-20220930.htm 10-Q amgn-20220930
0000318154false2022Q312/3100003181542022-01-012022-09-300000318154exch:XNGSus-gaap:CommonStockMember2022-01-012022-09-300000318154exch:XNGSamgn:A2.00SeniorNotesDue2026Member2022-01-012022-09-3000003181542022-10-31xbrli:shares0000318154us-gaap:ProductMember2022-07-012022-09-30iso4217:USD0000318154us-gaap:ProductMember2021-07-012021-09-300000318154us-gaap:ProductMember2022-01-012022-09-300000318154us-gaap:ProductMember2021-01-012021-09-300000318154us-gaap:ProductAndServiceOtherMember2022-07-012022-09-300000318154us-gaap:ProductAndServiceOtherMember2021-07-012021-09-300000318154us-gaap:ProductAndServiceOtherMember2022-01-012022-09-300000318154us-gaap:ProductAndServiceOtherMember2021-01-012021-09-3000003181542022-07-012022-09-3000003181542021-07-012021-09-3000003181542021-01-012021-09-30iso4217:USDxbrli:shares00003181542022-09-3000003181542021-12-310000318154us-gaap:CommonStockMember2021-12-310000318154us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2021-12-310000318154us-gaap:RetainedEarningsMember2021-12-310000318154us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310000318154us-gaap:RetainedEarningsMember2022-01-012022-03-3100003181542022-01-012022-03-310000318154us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310000318154us-gaap:CommonStockMember2022-01-012022-03-310000318154us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2022-01-012022-03-310000318154us-gaap:CommonStockMember2022-03-310000318154us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2022-03-310000318154us-gaap:RetainedEarningsMember2022-03-310000318154us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-3100003181542022-03-310000318154us-gaap:RetainedEarningsMember2022-04-012022-06-3000003181542022-04-012022-06-300000318154us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-300000318154us-gaap:CommonStockMember2022-04-012022-06-300000318154us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2022-04-012022-06-300000318154us-gaap:CommonStockMember2022-06-300000318154us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2022-06-300000318154us-gaap:RetainedEarningsMember2022-06-300000318154us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-3000003181542022-06-300000318154us-gaap:RetainedEarningsMember2022-07-012022-09-300000318154us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-300000318154us-gaap:CommonStockMember2022-07-012022-09-300000318154us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2022-07-012022-09-300000318154us-gaap:CommonStockMember2022-09-300000318154us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2022-09-300000318154us-gaap:RetainedEarningsMember2022-09-300000318154us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-300000318154us-gaap:CommonStockMember2020-12-310000318154us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2020-12-310000318154us-gaap:RetainedEarningsMember2020-12-310000318154us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-3100003181542020-12-310000318154us-gaap:RetainedEarningsMember2021-01-012021-03-3100003181542021-01-012021-03-310000318154us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-310000318154us-gaap:CommonStockMember2021-01-012021-03-310000318154us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2021-01-012021-03-310000318154us-gaap:CommonStockMember2021-03-310000318154us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2021-03-310000318154us-gaap:RetainedEarningsMember2021-03-310000318154us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-3100003181542021-03-310000318154us-gaap:RetainedEarningsMember2021-04-012021-06-3000003181542021-04-012021-06-300000318154us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-04-012021-06-300000318154us-gaap:CommonStockMember2021-04-012021-06-300000318154us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2021-04-012021-06-300000318154us-gaap:CommonStockMember2021-06-300000318154us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2021-06-300000318154us-gaap:RetainedEarningsMember2021-06-300000318154us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-3000003181542021-06-300000318154us-gaap:RetainedEarningsMember2021-07-012021-09-300000318154us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-07-012021-09-300000318154us-gaap:CommonStockMember2021-07-012021-09-300000318154us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2021-07-012021-09-300000318154us-gaap:CommonStockMember2021-09-300000318154us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2021-09-300000318154us-gaap:RetainedEarningsMember2021-09-300000318154us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-09-3000003181542021-09-30amgn:segment0000318154amgn:TeneobioMember2022-01-012022-09-300000318154amgn:TeneobioMember2022-09-300000318154amgn:TeneobioMemberamgn:RDTechnologyrightsMember2022-09-300000318154amgn:TeneobioMemberus-gaap:LicensingAgreementsMember2022-09-300000318154amgn:TeneobioMemberamgn:AMG340Memberus-gaap:InProcessResearchAndDevelopmentMember2022-09-300000318154amgn:TeneobioMemberamgn:RDTechnologyrightsMember2022-01-012022-09-300000318154amgn:TeneobioMemberus-gaap:LicensingAgreementsMember2022-01-012022-09-300000318154amgn:FivePrimeTherapeuticsIncMember2021-04-162021-04-160000318154amgn:FivePrimeTherapeuticsIncMember2021-04-160000318154amgn:GensentaIlacSanayiVsTicaretMember2022-06-282022-06-280000318154amgn:GensentaIlacSanayiVsTicaretMember2022-06-280000318154amgn:GensentaIlacSanayiVsTicaretMember2022-09-300000318154us-gaap:OtherOperatingIncomeExpenseMemberamgn:GensentaIlacSanayiVsTicaretMember2022-01-012022-09-300000318154country:USamgn:EnbrelMember2022-07-012022-09-300000318154us-gaap:NonUsMemberamgn:EnbrelMember2022-07-012022-09-300000318154amgn:EnbrelMember2022-07-012022-09-300000318154country:USamgn:EnbrelMember2021-07-012021-09-300000318154us-gaap:NonUsMemberamgn:EnbrelMember2021-07-012021-09-300000318154amgn:EnbrelMember2021-07-012021-09-300000318154amgn:ProliaMembercountry:US2022-07-012022-09-300000318154amgn:ProliaMemberus-gaap:NonUsMember2022-07-012022-09-300000318154amgn:ProliaMember2022-07-012022-09-300000318154amgn:ProliaMembercountry:US2021-07-012021-09-300000318154amgn:ProliaMemberus-gaap:NonUsMember2021-07-012021-09-300000318154amgn:ProliaMember2021-07-012021-09-300000318154amgn:OtezlaMembercountry:US2022-07-012022-09-300000318154amgn:OtezlaMemberus-gaap:NonUsMember2022-07-012022-09-300000318154amgn:OtezlaMember2022-07-012022-09-300000318154amgn:OtezlaMembercountry:US2021-07-012021-09-300000318154amgn:OtezlaMemberus-gaap:NonUsMember2021-07-012021-09-300000318154amgn:OtezlaMember2021-07-012021-09-300000318154amgn:XgevaMembercountry:US2022-07-012022-09-300000318154us-gaap:NonUsMemberamgn:XgevaMember2022-07-012022-09-300000318154amgn:XgevaMember2022-07-012022-09-300000318154amgn:XgevaMembercountry:US2021-07-012021-09-300000318154us-gaap:NonUsMemberamgn:XgevaMember2021-07-012021-09-300000318154amgn:XgevaMember2021-07-012021-09-300000318154country:USamgn:AranespMember2022-07-012022-09-300000318154us-gaap:NonUsMemberamgn:AranespMember2022-07-012022-09-300000318154amgn:AranespMember2022-07-012022-09-300000318154country:USamgn:AranespMember2021-07-012021-09-300000318154us-gaap:NonUsMemberamgn:AranespMember2021-07-012021-09-300000318154amgn:AranespMember2021-07-012021-09-300000318154amgn:RepathaevolocumabMembercountry:US2022-07-012022-09-300000318154us-gaap:NonUsMemberamgn:RepathaevolocumabMember2022-07-012022-09-300000318154amgn:RepathaevolocumabMember2022-07-012022-09-300000318154amgn:RepathaevolocumabMembercountry:US2021-07-012021-09-300000318154us-gaap:NonUsMemberamgn:RepathaevolocumabMember2021-07-012021-09-300000318154amgn:RepathaevolocumabMember2021-07-012021-09-300000318154amgn:KyprolisMembercountry:US2022-07-012022-09-300000318154us-gaap:NonUsMemberamgn:KyprolisMember2022-07-012022-09-300000318154amgn:KyprolisMember2022-07-012022-09-300000318154amgn:KyprolisMembercountry:US2021-07-012021-09-300000318154us-gaap:NonUsMemberamgn:KyprolisMember2021-07-012021-09-300000318154amgn:KyprolisMember2021-07-012021-09-300000318154amgn:NeulastaMembercountry:US2022-07-012022-09-300000318154us-gaap:NonUsMemberamgn:NeulastaMember2022-07-012022-09-300000318154amgn:NeulastaMember2022-07-012022-09-300000318154amgn:NeulastaMembercountry:US2021-07-012021-09-300000318154us-gaap:NonUsMemberamgn:NeulastaMember2021-07-012021-09-300000318154amgn:NeulastaMember2021-07-012021-09-300000318154amgn:NplateMembercountry:US2022-07-012022-09-300000318154us-gaap:NonUsMemberamgn:NplateMember2022-07-012022-09-300000318154amgn:NplateMember2022-07-012022-09-300000318154amgn:NplateMembercountry:US2021-07-012021-09-300000318154us-gaap:NonUsMemberamgn:NplateMember2021-07-012021-09-300000318154amgn:NplateMember2021-07-012021-09-300000318154amgn:OtherProductsMembercountry:US2022-07-012022-09-300000318154amgn:OtherProductsMemberus-gaap:NonUsMember2022-07-012022-09-300000318154amgn:OtherProductsMember2022-07-012022-09-300000318154amgn:OtherProductsMembercountry:US2021-07-012021-09-300000318154amgn:OtherProductsMemberus-gaap:NonUsMember2021-07-012021-09-300000318154amgn:OtherProductsMember2021-07-012021-09-300000318154country:USus-gaap:ProductMember2022-07-012022-09-300000318154us-gaap:NonUsMemberus-gaap:ProductMember2022-07-012022-09-300000318154country:USus-gaap:ProductMember2021-07-012021-09-300000318154us-gaap:NonUsMemberus-gaap:ProductMember2021-07-012021-09-300000318154country:USamgn:EnbrelMember2022-01-012022-09-300000318154us-gaap:NonUsMemberamgn:EnbrelMember2022-01-012022-09-300000318154amgn:EnbrelMember2022-01-012022-09-300000318154country:USamgn:EnbrelMember2021-01-012021-09-300000318154us-gaap:NonUsMemberamgn:EnbrelMember2021-01-012021-09-300000318154amgn:EnbrelMember2021-01-012021-09-300000318154amgn:ProliaMembercountry:US2022-01-012022-09-300000318154amgn:ProliaMemberus-gaap:NonUsMember2022-01-012022-09-300000318154amgn:ProliaMember2022-01-012022-09-300000318154amgn:ProliaMembercountry:US2021-01-012021-09-300000318154amgn:ProliaMemberus-gaap:NonUsMember2021-01-012021-09-300000318154amgn:ProliaMember2021-01-012021-09-300000318154amgn:OtezlaMembercountry:US2022-01-012022-09-300000318154amgn:OtezlaMemberus-gaap:NonUsMember2022-01-012022-09-300000318154amgn:OtezlaMember2022-01-012022-09-300000318154amgn:OtezlaMembercountry:US2021-01-012021-09-300000318154amgn:OtezlaMemberus-gaap:NonUsMember2021-01-012021-09-300000318154amgn:OtezlaMember2021-01-012021-09-300000318154amgn:XgevaMembercountry:US2022-01-012022-09-300000318154us-gaap:NonUsMemberamgn:XgevaMember2022-01-012022-09-300000318154amgn:XgevaMember2022-01-012022-09-300000318154amgn:XgevaMembercountry:US2021-01-012021-09-300000318154us-gaap:NonUsMemberamgn:XgevaMember2021-01-012021-09-300000318154amgn:XgevaMember2021-01-012021-09-300000318154country:USamgn:AranespMember2022-01-012022-09-300000318154us-gaap:NonUsMemberamgn:AranespMember2022-01-012022-09-300000318154amgn:AranespMember2022-01-012022-09-300000318154country:USamgn:AranespMember2021-01-012021-09-300000318154us-gaap:NonUsMemberamgn:AranespMember2021-01-012021-09-300000318154amgn:AranespMember2021-01-012021-09-300000318154amgn:RepathaevolocumabMembercountry:US2022-01-012022-09-300000318154us-gaap:NonUsMemberamgn:RepathaevolocumabMember2022-01-012022-09-300000318154amgn:RepathaevolocumabMember2022-01-012022-09-300000318154amgn:RepathaevolocumabMembercountry:US2021-01-012021-09-300000318154us-gaap:NonUsMemberamgn:RepathaevolocumabMember2021-01-012021-09-300000318154amgn:RepathaevolocumabMember2021-01-012021-09-300000318154amgn:KyprolisMembercountry:US2022-01-012022-09-300000318154us-gaap:NonUsMemberamgn:KyprolisMember2022-01-012022-09-300000318154amgn:KyprolisMember2022-01-012022-09-300000318154amgn:KyprolisMembercountry:US2021-01-012021-09-300000318154us-gaap:NonUsMemberamgn:KyprolisMember2021-01-012021-09-300000318154amgn:KyprolisMember2021-01-012021-09-300000318154amgn:NeulastaMembercountry:US2022-01-012022-09-300000318154us-gaap:NonUsMemberamgn:NeulastaMember2022-01-012022-09-300000318154amgn:NeulastaMember2022-01-012022-09-300000318154amgn:NeulastaMembercountry:US2021-01-012021-09-300000318154us-gaap:NonUsMemberamgn:NeulastaMember2021-01-012021-09-300000318154amgn:NeulastaMember2021-01-012021-09-300000318154amgn:NplateMembercountry:US2022-01-012022-09-300000318154us-gaap:NonUsMemberamgn:NplateMember2022-01-012022-09-300000318154amgn:NplateMember2022-01-012022-09-300000318154amgn:NplateMembercountry:US2021-01-012021-09-300000318154us-gaap:NonUsMemberamgn:NplateMember2021-01-012021-09-300000318154amgn:NplateMember2021-01-012021-09-300000318154amgn:OtherProductsMembercountry:US2022-01-012022-09-300000318154amgn:OtherProductsMemberus-gaap:NonUsMember2022-01-012022-09-300000318154amgn:OtherProductsMember2022-01-012022-09-300000318154amgn:OtherProductsMembercountry:US2021-01-012021-09-300000318154amgn:OtherProductsMemberus-gaap:NonUsMember2021-01-012021-09-300000318154amgn:OtherProductsMember2021-01-012021-09-300000318154country:USus-gaap:ProductMember2022-01-012022-09-300000318154us-gaap:NonUsMemberus-gaap:ProductMember2022-01-012022-09-300000318154country:USus-gaap:ProductMember2021-01-012021-09-300000318154us-gaap:NonUsMemberus-gaap:ProductMember2021-01-012021-09-30xbrli:pure0000318154us-gaap:DomesticCountryMember2021-05-310000318154us-gaap:DomesticCountryMember2022-04-280000318154us-gaap:USTreasurySecuritiesMember2022-09-300000318154us-gaap:USTreasuryBillSecuritiesMember2022-09-300000318154us-gaap:MoneyMarketFundsMember2022-09-300000318154amgn:OtherShortTermInterestBearingSecuritiesMember2022-09-300000318154us-gaap:USTreasurySecuritiesMember2021-12-310000318154us-gaap:USTreasuryBillSecuritiesMember2021-12-310000318154us-gaap:MoneyMarketFundsMember2021-12-310000318154amgn:OtherShortTermInterestBearingSecuritiesMember2021-12-310000318154amgn:AvailableForSalesInvestmentsMember2022-09-300000318154amgn:AvailableForSalesInvestmentsMember2021-12-310000318154us-gaap:FairValueInputsLevel1Member2022-09-300000318154us-gaap:FairValueInputsLevel1Member2021-12-310000318154amgn:BeiGeneMember2022-09-300000318154amgn:BeiGeneMember2021-12-310000318154amgn:BeiGeneMember2022-07-012022-09-300000318154amgn:BeiGeneMember2021-07-012021-09-300000318154amgn:BeiGeneMember2022-01-012022-09-300000318154amgn:BeiGeneMember2021-01-012021-09-300000318154amgn:NeumoraTherapeuticsIncMember2021-09-300000318154amgn:NeumoraTherapeuticsIncMember2021-09-302021-09-300000318154amgn:NeumoraTherapeuticsIncMember2022-07-012022-09-300000318154amgn:NeumoraTherapeuticsIncMember2022-09-300000318154amgn:NeumoraTherapeuticsIncMember2021-12-310000318154amgn:NeumoraTherapeuticsIncMember2022-01-012022-09-300000318154us-gaap:FairValueMeasuredAtNetAssetValuePerShareMembersrt:PartnershipInterestMember2022-09-300000318154us-gaap:FairValueMeasuredAtNetAssetValuePerShareMembersrt:PartnershipInterestMember2021-12-310000318154us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2022-09-300000318154us-gaap:FairValueMeasuredAtNetAssetValuePerShareMembersrt:PartnershipInterestMember2022-07-012022-09-300000318154us-gaap:FairValueMeasuredAtNetAssetValuePerShareMembersrt:PartnershipInterestMember2021-07-012021-09-300000318154us-gaap:FairValueMeasuredAtNetAssetValuePerShareMembersrt:PartnershipInterestMember2022-01-012022-09-300000318154us-gaap:FairValueMeasuredAtNetAssetValuePerShareMembersrt:PartnershipInterestMember2021-01-012021-09-300000318154us-gaap:DevelopedTechnologyRightsMember2022-09-300000318154us-gaap:DevelopedTechnologyRightsMember2021-12-310000318154us-gaap:LicensingAgreementsMember2022-09-300000318154us-gaap:LicensingAgreementsMember2021-12-310000318154us-gaap:MarketingRelatedIntangibleAssetsMember2022-09-300000318154us-gaap:MarketingRelatedIntangibleAssetsMember2021-12-310000318154amgn:AcquiredResearchAndDevelopmentTechnologyRightsMember2022-09-300000318154amgn:AcquiredResearchAndDevelopmentTechnologyRightsMember2021-12-310000318154us-gaap:InProcessResearchAndDevelopmentMember2022-09-300000318154us-gaap:InProcessResearchAndDevelopmentMember2021-12-310000318154us-gaap:NotesPayableToBanksMemberamgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember2022-09-30iso4217:CHF0000318154us-gaap:NotesPayableToBanksMemberamgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember2021-12-310000318154amgn:TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMemberus-gaap:NotesPayableToBanksMember2022-09-300000318154amgn:TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMemberus-gaap:NotesPayableToBanksMember2021-12-310000318154amgn:ThreePointSixTwoFivePercentNotesDue2024Memberus-gaap:NotesPayableToBanksMember2022-09-300000318154amgn:ThreePointSixTwoFivePercentNotesDue2024Memberus-gaap:NotesPayableToBanksMember2021-12-310000318154amgn:OnePointNineZeroPercentNotesDueTwoZeroTwoFiveMemberus-gaap:NotesPayableToBanksMember2022-09-300000318154amgn:OnePointNineZeroPercentNotesDueTwoZeroTwoFiveMemberus-gaap:NotesPayableToBanksMember2021-12-310000318154us-gaap:NotesPayableToBanksMemberamgn:ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember2022-09-300000318154us-gaap:NotesPayableToBanksMemberamgn:ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember2021-12-310000318154us-gaap:NotesPayableToBanksMemberamgn:TwoPercentEuroNotesDueTwoThousandTwentySixMember2022-09-30iso4217:EUR0000318154us-gaap:NotesPayableToBanksMemberamgn:TwoPercentEuroNotesDueTwoThousandTwentySixMember2021-12-310000318154us-gaap:NotesPayableToBanksMemberamgn:TwoPointSixZeroNotesDueTwoZeroTwoSixMember2022-09-300000318154us-gaap:NotesPayableToBanksMemberamgn:TwoPointSixZeroNotesDueTwoZeroTwoSixMember2021-12-310000318154amgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Memberus-gaap:NotesPayableToBanksMember2022-09-30iso4217:GBP0000318154amgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Memberus-gaap:NotesPayableToBanksMember2021-12-310000318154amgn:TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMemberus-gaap:NotesPayableToBanksMember2022-09-300000318154amgn:TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMemberus-gaap:NotesPayableToBanksMember2021-12-310000318154amgn:ThreePointTwoZeroNotesDue2027Memberus-gaap:NotesPayableToBanksMember2022-09-300000318154amgn:ThreePointTwoZeroNotesDue2027Memberus-gaap:NotesPayableToBanksMember2021-12-310000318154us-gaap:NotesPayableToBanksMemberamgn:OnePointSixFivePercent2028NotesMember2022-09-300000318154us-gaap:NotesPayableToBanksMemberamgn:OnePointSixFivePercent2028NotesMember2021-12-310000318154us-gaap:NotesPayableToBanksMemberamgn:A3002029NotesMember2022-09-300000318154us-gaap:NotesPayableToBanksMemberamgn:A3002029NotesMember2021-12-310000318154amgn:A4052029NotesMemberus-gaap:NotesPayableToBanksMember2022-09-300000318154amgn:A4052029NotesMemberus-gaap:NotesPayableToBanksMember2021-12-310000318154us-gaap:NotesPayableToBanksMemberamgn:FourPercentPoundSterlingNotesDue2029Member2022-09-300000318154us-gaap:NotesPayableToBanksMemberamgn:FourPercentPoundSterlingNotesDue2029Member2021-12-310000318154amgn:TwoPointFourFivePercentNotesDue2030Memberus-gaap:NotesPayableToBanksMember2022-09-300000318154amgn:TwoPointFourFivePercentNotesDue2030Memberus-gaap:NotesPayableToBanksMember2021-12-310000318154us-gaap:NotesPayableToBanksMemberamgn:TwoPointThreeZeroPercentNotesDue2031Member2022-09-300000318154us-gaap:NotesPayableToBanksMemberamgn:TwoPointThreeZeroPercentNotesDue2031Member2021-12-310000318154us-gaap:NotesPayableToBanksMemberamgn:TwoPointZeroPercent2032NotesMemberMember2022-09-300000318154us-gaap:NotesPayableToBanksMemberamgn:TwoPointZeroPercent2032NotesMemberMember2021-12-310000318154us-gaap:NotesPayableToBanksMemberamgn:A3352032NotesMember2022-09-300000318154us-gaap:NotesPayableToBanksMemberamgn:A3352032NotesMember2021-12-310000318154amgn:A4202033NotesMemberus-gaap:NotesPayableToBanksMember2022-09-300000318154amgn:A4202033NotesMemberus-gaap:NotesPayableToBanksMember2021-12-310000318154us-gaap:NotesPayableToBanksMemberamgn:SixPointThreeSevenFivePercentNotesDue2037Member2022-09-300000318154us-gaap:NotesPayableToBanksMemberamgn:SixPointThreeSevenFivePercentNotesDue2037Member2021-12-310000318154us-gaap:NotesPayableToBanksMemberamgn:SixPointNineZeroPercentNotesDue2038Member2022-09-300000318154us-gaap:NotesPayableToBanksMemberamgn:SixPointNineZeroPercentNotesDue2038Member2021-12-310000318154us-gaap:NotesPayableToBanksMemberamgn:SixPointFourZeroPercentNotesDue2039Member2022-09-300000318154us-gaap:NotesPayableToBanksMemberamgn:SixPointFourZeroPercentNotesDue2039Member2021-12-310000318154us-gaap:NotesPayableToBanksMemberamgn:ThreePointOneFivePercentNotesDue2040Member2022-09-300000318154us-gaap:NotesPayableToBanksMemberamgn:ThreePointOneFivePercentNotesDue2040Member2021-12-310000318154amgn:FivePointSevenFivePercentNotesDue2040Memberus-gaap:NotesPayableToBanksMember2022-09-300000318154amgn:FivePointSevenFivePercentNotesDue2040Memberus-gaap:NotesPayableToBanksMember2021-12-310000318154amgn:TwoPointEightZeroPercent2041NotesMemberus-gaap:NotesPayableToBanksMember2022-09-300000318154amgn:TwoPointEightZeroPercent2041NotesMemberus-gaap:NotesPayableToBanksMember2021-12-310000318154us-gaap:NotesPayableToBanksMemberamgn:FourPointNineFivePercentNotesDue2041Member2022-09-300000318154us-gaap:NotesPayableToBanksMemberamgn:FourPointNineFivePercentNotesDue2041Member2021-12-310000318154us-gaap:NotesPayableToBanksMemberamgn:FivePointOneFivePercentNotesDue2041Member2022-09-300000318154us-gaap:NotesPayableToBanksMemberamgn:FivePointOneFivePercentNotesDue2041Member2021-12-310000318154us-gaap:NotesPayableToBanksMemberamgn:FivePointSixFivePercentNotesDue2042Member2022-09-300000318154us-gaap:NotesPayableToBanksMemberamgn:FivePointSixFivePercentNotesDue2042Member2021-12-310000318154us-gaap:NotesPayableToBanksMemberamgn:FivePointThreeSevenFivePercentNotesDue2043Member2022-09-300000318154us-gaap:NotesPayableToBanksMemberamgn:FivePointThreeSevenFivePercentNotesDue2043Member2021-12-310000318154us-gaap:NotesPayableToBanksMemberamgn:FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember2022-09-300000318154us-gaap:NotesPayableToBanksMemberamgn:FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember2021-12-310000318154amgn:FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMemberus-gaap:NotesPayableToBanksMember2022-09-300000318154amgn:FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMemberus-gaap:NotesPayableToBanksMember2021-12-310000318154us-gaap:NotesPayableToBanksMemberamgn:ThreePointThreeSevenFivePercentNotesDue2050Member2022-09-300000318154us-gaap:NotesPayableToBanksMemberamgn:ThreePointThreeSevenFivePercentNotesDue2050Member2021-12-310000318154us-gaap:NotesPayableToBanksMemberamgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember2022-09-300000318154us-gaap:NotesPayableToBanksMemberamgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember2021-12-310000318154us-gaap:NotesPayableToBanksMemberamgn:A300NotesDue20523002052NotesMember2022-09-300000318154us-gaap:NotesPayableToBanksMemberamgn:A300NotesDue20523002052NotesMember2021-12-310000318154amgn:A4202052NotesMemberus-gaap:NotesPayableToBanksMember2022-09-300000318154amgn:A4202052NotesMemberus-gaap:NotesPayableToBanksMember2021-12-310000318154us-gaap:NotesPayableToBanksMemberamgn:A48752053NotesMember2022-09-300000318154us-gaap:NotesPayableToBanksMemberamgn:A48752053NotesMember2021-12-310000318154amgn:TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMemberus-gaap:NotesPayableToBanksMember2022-09-300000318154amgn:TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMemberus-gaap:NotesPayableToBanksMember2021-12-310000318154us-gaap:NotesPayableToBanksMemberamgn:A4402062NotesMember2022-09-300000318154us-gaap:NotesPayableToBanksMemberamgn:A4402062NotesMember2021-12-310000318154us-gaap:NotesPayableToBanksMemberamgn:OtherNotesDue2097Member2022-09-300000318154us-gaap:NotesPayableToBanksMemberamgn:OtherNotesDue2097Member2021-12-310000318154us-gaap:NotesPayableToBanksMember2022-03-310000318154us-gaap:NotesPayableToBanksMemberamgn:A3002029NotesMember2022-03-310000318154us-gaap:NotesPayableToBanksMemberamgn:A3352032NotesMember2022-03-310000318154amgn:A4202052NotesMember2022-03-310000318154amgn:A4202052NotesMemberus-gaap:NotesPayableToBanksMember2022-03-310000318154us-gaap:NotesPayableToBanksMemberamgn:A4402062NotesMember2022-03-310000318154us-gaap:NotesPayableToBanksMemberamgn:A3352032NotesMember2022-01-012022-09-300000318154us-gaap:NotesPayableToBanksMemberamgn:A3002029NotesMember2022-01-012022-09-300000318154us-gaap:NotesPayableToBanksMemberamgn:A4402062NotesMember2022-01-012022-09-300000318154amgn:A4202052NotesMemberus-gaap:NotesPayableToBanksMember2022-01-012022-09-300000318154srt:MinimumMemberus-gaap:DebtSecuritiesPayableMember2022-01-012022-09-300000318154srt:MaximumMemberus-gaap:DebtSecuritiesPayableMember2022-01-012022-09-300000318154us-gaap:NotesPayableToBanksMember2022-09-300000318154us-gaap:NotesPayableToBanksMemberamgn:A48752053NotesMember2022-07-012022-09-300000318154amgn:A4202033NotesMemberus-gaap:NotesPayableToBanksMember2022-07-012022-09-300000318154amgn:A4052029NotesMemberus-gaap:NotesPayableToBanksMember2022-07-012022-09-300000318154amgn:AcceleratedStockRepurchaseAgreementMember2022-02-24amgn:financial_institution0000318154amgn:AcceleratedStockRepurchaseAgreementMember2022-02-252022-02-250000318154amgn:AcceleratedStockRepurchaseAgreementMemberus-gaap:RetainedEarningsMember2022-02-252022-02-250000318154us-gaap:CommonStockIncludingAdditionalPaidInCapitalMemberamgn:AcceleratedStockRepurchaseAgreementMember2022-02-252022-02-250000318154amgn:AcceleratedStockRepurchaseAgreementMember2022-07-012022-09-300000318154amgn:AcceleratedStockRepurchaseAgreementMemberus-gaap:RetainedEarningsMember2022-07-012022-09-300000318154amgn:AcceleratedStockRepurchaseAgreementMember2022-01-012022-09-300000318154us-gaap:SubsequentEventMember2022-10-3100003181542022-06-012022-06-3000003181542021-12-012021-12-3100003181542022-08-012022-08-3100003181542022-03-012022-03-3100003181542022-09-012022-09-300000318154srt:ScenarioForecastMember2022-12-012022-12-300000318154us-gaap:SubsequentEventMember2022-10-012022-10-310000318154us-gaap:AccumulatedTranslationAdjustmentMember2021-12-310000318154us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-12-310000318154us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-12-310000318154amgn:AccumulatedOtherAdjustmentAttributabletoParentMember2021-12-310000318154us-gaap:AccumulatedTranslationAdjustmentMember2022-01-012022-03-310000318154us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-01-012022-03-310000318154us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-01-012022-03-310000318154amgn:AccumulatedOtherAdjustmentAttributabletoParentMember2022-01-012022-03-310000318154us-gaap:AccumulatedTranslationAdjustmentMember2022-03-310000318154us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-03-310000318154us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-03-310000318154amgn:AccumulatedOtherAdjustmentAttributabletoParentMember2022-03-310000318154us-gaap:AccumulatedTranslationAdjustmentMember2022-04-012022-06-300000318154us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-04-012022-06-300000318154us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-04-012022-06-300000318154amgn:AccumulatedOtherAdjustmentAttributabletoParentMember2022-04-012022-06-300000318154us-gaap:AccumulatedTranslationAdjustmentMember2022-06-300000318154us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-06-300000318154us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-06-300000318154amgn:AccumulatedOtherAdjustmentAttributabletoParentMember2022-06-300000318154us-gaap:AccumulatedTranslationAdjustmentMember2021-07-012021-09-300000318154us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-07-012021-09-300000318154us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-07-012021-09-300000318154amgn:AccumulatedOtherAdjustmentAttributabletoParentMember2021-07-012021-09-300000318154us-gaap:AccumulatedTranslationAdjustmentMember2022-09-300000318154us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-09-300000318154us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-09-300000318154amgn:AccumulatedOtherAdjustmentAttributabletoParentMember2022-09-300000318154us-gaap:CashFlowHedgingMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ForeignExchangeContractMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:ProductMember2022-07-012022-09-300000318154us-gaap:CashFlowHedgingMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ForeignExchangeContractMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:ProductMember2021-07-012021-09-300000318154us-gaap:CashFlowHedgingMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberamgn:CrossCurrencySwapContractsMember2022-07-012022-09-300000318154us-gaap:CashFlowHedgingMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberamgn:CrossCurrencySwapContractsMember2021-07-012021-09-300000318154us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-300000318154us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2021-07-012021-09-300000318154us-gaap:CashFlowHedgingMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ForeignExchangeContractMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:ProductMember2022-01-012022-09-300000318154us-gaap:CashFlowHedgingMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ForeignExchangeContractMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:ProductMember2021-01-012021-09-300000318154us-gaap:CashFlowHedgingMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberamgn:CrossCurrencySwapContractsMember2022-01-012022-09-300000318154us-gaap:CashFlowHedgingMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberamgn:CrossCurrencySwapContractsMember2021-01-012021-09-300000318154us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2022-01-012022-09-300000318154us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2021-01-012021-09-300000318154us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel1Member2022-09-300000318154us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMember2022-09-300000318154us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel3Member2022-09-300000318154us-gaap:USTreasuryBillSecuritiesMemberus-gaap:FairValueInputsLevel1Member2022-09-300000318154us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasuryBillSecuritiesMember2022-09-300000318154us-gaap:USTreasuryBillSecuritiesMemberus-gaap:FairValueInputsLevel3Member2022-09-300000318154us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2022-09-300000318154us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2022-09-300000318154us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMember2022-09-300000318154us-gaap:FairValueInputsLevel1Memberamgn:OtherShortTermInterestBearingSecuritiesMember2022-09-300000318154us-gaap:FairValueInputsLevel2Memberamgn:OtherShortTermInterestBearingSecuritiesMember2022-09-300000318154amgn:OtherShortTermInterestBearingSecuritiesMemberus-gaap:FairValueInputsLevel3Member2022-09-300000318154us-gaap:FairValueInputsLevel2Member2022-09-300000318154us-gaap:FairValueInputsLevel3Member2022-09-300000318154us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignExchangeContractMember2022-09-300000318154us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeContractMember2022-09-300000318154us-gaap:ForeignExchangeContractMemberus-gaap:FairValueInputsLevel3Member2022-09-300000318154us-gaap:ForeignExchangeContractMember2022-09-300000318154us-gaap:FairValueInputsLevel1Memberamgn:CrossCurrencySwapContractsMember2022-09-300000318154us-gaap:FairValueInputsLevel2Memberamgn:CrossCurrencySwapContractsMember2022-09-300000318154us-gaap:FairValueInputsLevel3Memberamgn:CrossCurrencySwapContractsMember2022-09-300000318154amgn:CrossCurrencySwapContractsMember2022-09-300000318154us-gaap:InterestRateSwapMemberus-gaap:FairValueInputsLevel1Member2022-09-300000318154us-gaap:FairValueInputsLevel2Memberus-gaap:InterestRateSwapMember2022-09-300000318154us-gaap:InterestRateSwapMemberus-gaap:FairValueInputsLevel3Member2022-09-300000318154us-gaap:InterestRateSwapMember2022-09-300000318154us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel1Member2021-12-310000318154us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMember2021-12-310000318154us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel3Member2021-12-310000318154us-gaap:USTreasuryBillSecuritiesMemberus-gaap:FairValueInputsLevel1Member2021-12-310000318154us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasuryBillSecuritiesMember2021-12-310000318154us-gaap:USTreasuryBillSecuritiesMemberus-gaap:FairValueInputsLevel3Member2021-12-310000318154us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2021-12-310000318154us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2021-12-310000318154us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMember2021-12-310000318154us-gaap:FairValueInputsLevel1Memberamgn:OtherShortTermInterestBearingSecuritiesMember2021-12-310000318154us-gaap:FairValueInputsLevel2Memberamgn:OtherShortTermInterestBearingSecuritiesMember2021-12-310000318154amgn:OtherShortTermInterestBearingSecuritiesMemberus-gaap:FairValueInputsLevel3Member2021-12-310000318154us-gaap:FairValueInputsLevel2Member2021-12-310000318154us-gaap:FairValueInputsLevel3Member2021-12-310000318154us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignExchangeContractMember2021-12-310000318154us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeContractMember2021-12-310000318154us-gaap:ForeignExchangeContractMemberus-gaap:FairValueInputsLevel3Member2021-12-310000318154us-gaap:ForeignExchangeContractMember2021-12-310000318154us-gaap:FairValueInputsLevel1Memberamgn:CrossCurrencySwapContractsMember2021-12-310000318154us-gaap:FairValueInputsLevel2Memberamgn:CrossCurrencySwapContractsMember2021-12-310000318154us-gaap:FairValueInputsLevel3Memberamgn:CrossCurrencySwapContractsMember2021-12-310000318154amgn:CrossCurrencySwapContractsMember2021-12-310000318154us-gaap:InterestRateSwapMemberus-gaap:FairValueInputsLevel1Member2021-12-310000318154us-gaap:FairValueInputsLevel2Memberus-gaap:InterestRateSwapMember2021-12-310000318154us-gaap:InterestRateSwapMemberus-gaap:FairValueInputsLevel3Member2021-12-310000318154us-gaap:InterestRateSwapMember2021-12-310000318154amgn:TeneobioIncMember2022-09-300000318154amgn:TeneobioIncMember2021-12-310000318154amgn:BeiGeneMember2022-09-300000318154amgn:BeiGeneMember2021-12-310000318154us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForwardContractsMember2022-09-300000318154us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForwardContractsMember2021-12-310000318154us-gaap:CashFlowHedgingMemberamgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMemberamgn:CrossCurrencySwapContractsMember2022-09-300000318154us-gaap:CashFlowHedgingMembercurrency:CHFamgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMemberamgn:CrossCurrencySwapContractsMember2022-09-300000318154currency:USDus-gaap:CashFlowHedgingMemberamgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMemberamgn:CrossCurrencySwapContractsMember2022-09-300000318154us-gaap:CashFlowHedgingMemberamgn:TwoPercentEuroNotesDueTwoThousandTwentySixMemberamgn:CrossCurrencySwapContractsMember2022-09-300000318154us-gaap:CashFlowHedgingMembercurrency:EURamgn:TwoPercentEuroNotesDueTwoThousandTwentySixMemberamgn:CrossCurrencySwapContractsMember2022-09-300000318154currency:USDus-gaap:CashFlowHedgingMemberamgn:TwoPercentEuroNotesDueTwoThousandTwentySixMemberamgn:CrossCurrencySwapContractsMember2022-09-300000318154us-gaap:CashFlowHedgingMemberamgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Memberamgn:CrossCurrencySwapContractsMember2022-09-300000318154us-gaap:CashFlowHedgingMembercurrency:GBPamgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Memberamgn:CrossCurrencySwapContractsMember2022-09-300000318154currency:USDus-gaap:CashFlowHedgingMemberamgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Memberamgn:CrossCurrencySwapContractsMember2022-09-300000318154us-gaap:CashFlowHedgingMemberamgn:FourPercentPoundSterlingNotesDue2029Memberamgn:CrossCurrencySwapContractsMember2022-09-300000318154us-gaap:CashFlowHedgingMembercurrency:GBPamgn:FourPercentPoundSterlingNotesDue2029Memberamgn:CrossCurrencySwapContractsMember2022-09-300000318154currency:USDus-gaap:CashFlowHedgingMemberamgn:FourPercentPoundSterlingNotesDue2029Memberamgn:CrossCurrencySwapContractsMember2022-09-300000318154us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMember2022-07-012022-09-300000318154us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMember2021-07-012021-09-300000318154us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMember2022-01-012022-09-300000318154us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMember2021-01-012021-09-300000318154us-gaap:CashFlowHedgingMemberamgn:CrossCurrencySwapContractsMember2022-07-012022-09-300000318154us-gaap:CashFlowHedgingMemberamgn:CrossCurrencySwapContractsMember2021-07-012021-09-300000318154us-gaap:CashFlowHedgingMemberamgn:CrossCurrencySwapContractsMember2022-01-012022-09-300000318154us-gaap:CashFlowHedgingMemberamgn:CrossCurrencySwapContractsMember2021-01-012021-09-300000318154us-gaap:CashFlowHedgingMember2022-07-012022-09-300000318154us-gaap:CashFlowHedgingMember2021-07-012021-09-300000318154us-gaap:CashFlowHedgingMember2022-01-012022-09-300000318154us-gaap:CashFlowHedgingMember2021-01-012021-09-300000318154us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2021-12-310000318154us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2022-09-300000318154amgn:LongTermDebtCurrentMaturitiesMember2022-09-300000318154amgn:LongTermDebtCurrentMaturitiesMember2021-12-310000318154us-gaap:LongTermDebtMember2022-09-300000318154us-gaap:LongTermDebtMember2021-12-310000318154us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ForeignExchangeContractMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:ProductMember2022-07-012022-09-300000318154us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ForeignExchangeContractMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:ProductMember2022-01-012022-09-300000318154us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberamgn:CrossCurrencySwapContractsMember2022-07-012022-09-300000318154us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberamgn:CrossCurrencySwapContractsMember2022-01-012022-09-300000318154us-gaap:InterestRateSwapMember2022-07-012022-09-300000318154us-gaap:InterestRateSwapMember2022-01-012022-09-300000318154us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ForeignExchangeContractMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:ProductMember2021-07-012021-09-300000318154us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ForeignExchangeContractMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:ProductMember2021-01-012021-09-300000318154us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberamgn:CrossCurrencySwapContractsMember2021-07-012021-09-300000318154us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberamgn:CrossCurrencySwapContractsMember2021-01-012021-09-300000318154us-gaap:InterestRateSwapMember2021-07-012021-09-300000318154us-gaap:InterestRateSwapMember2021-01-012021-09-300000318154us-gaap:NondesignatedMemberus-gaap:ForwardContractsMember2022-09-300000318154us-gaap:NondesignatedMemberus-gaap:ForwardContractsMember2021-12-310000318154us-gaap:DesignatedAsHedgingInstrumentMemberamgn:OtherCurrentNoncurrentAssetsMemberus-gaap:ForeignExchangeContractMember2022-09-300000318154us-gaap:DesignatedAsHedgingInstrumentMemberamgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMemberus-gaap:ForeignExchangeContractMember2022-09-300000318154us-gaap:DesignatedAsHedgingInstrumentMemberamgn:OtherCurrentNoncurrentAssetsMemberamgn:CrossCurrencySwapContractsMember2022-09-300000318154us-gaap:DesignatedAsHedgingInstrumentMemberamgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMemberamgn:CrossCurrencySwapContractsMember2022-09-300000318154us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberamgn:OtherCurrentNoncurrentAssetsMember2022-09-300000318154us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberamgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember2022-09-300000318154us-gaap:DesignatedAsHedgingInstrumentMember2022-09-300000318154us-gaap:DesignatedAsHedgingInstrumentMemberamgn:OtherCurrentNoncurrentAssetsMemberus-gaap:ForeignExchangeContractMember2021-12-310000318154us-gaap:DesignatedAsHedgingInstrumentMemberamgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMemberus-gaap:ForeignExchangeContractMember2021-12-310000318154us-gaap:DesignatedAsHedgingInstrumentMemberamgn:OtherCurrentNoncurrentAssetsMemberamgn:CrossCurrencySwapContractsMember2021-12-310000318154us-gaap:DesignatedAsHedgingInstrumentMemberamgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMemberamgn:CrossCurrencySwapContractsMember2021-12-310000318154us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberamgn:OtherCurrentNoncurrentAssetsMember2021-12-310000318154us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberamgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember2021-12-310000318154us-gaap:DesignatedAsHedgingInstrumentMember2021-12-310000318154amgn:ChemoCentryxIncSecuritiesMattersMember2021-05-052021-06-08amgn:lawsuit0000318154amgn:ChemoCentryxIncMemberus-gaap:SubsequentEventMember2022-10-200000318154amgn:ChemoCentryxIncMemberus-gaap:SubsequentEventMember2022-10-202022-10-20

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2022
or
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Commission File Number: 001-37702
Amgen Inc.
(Exact name of registrant as specified in its charter)
Delaware 95-3540776
(State or other jurisdiction of
incorporation or organization)
 (I.R.S. Employer
Identification No.)
One Amgen Center Drive 91320-1799
Thousand Oaks
California
(Address of principal executive offices) (Zip Code)
(805) 447-1000
(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common stock, $0.0001 par valueAMGNThe Nasdaq Stock Market LLC
2.00% Senior Notes due 2026AMGN26The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No 
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes  No 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filerAccelerated filerNon-accelerated filer
Smaller reporting companyEmerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). 
Yes No 
As of October 31, 2022, the registrant had 533,579,206 shares of common stock, $0.0001 par value, outstanding.



AMGEN INC.
INDEX
i


Defined Terms and Products
Defined terms
We use several terms in this Form 10-Q, including but not limited to those that are finance, regulation and disease-state related as well as names of other companies, which are given below.
TermDescription
ANDAAbbreviated New Drug Application
AOCIaccumulated other comprehensive income (loss)
ASRaccelerated share repurchase
BeiGeneBeiGene, Ltd.
BergamoLaboratorio Quimico Farmaceutico Bergamo Ltda
ChemoCentryxChemoCentryx, Inc.
CMSCenters for Medicare & Medicaid Services
COVID-19coronavirus disease 2019
EczacıbaşıEIS Eczacıbaşı İlaç, Sınai ve Finansal Yatırımlar Sanayi ve Ticaret A.Ş.
EPSearnings per share
FASBFinancial Accounting Standards Board
FDAU.S. Food and Drug Administration
FitchFitch Ratings, Inc.
Five PrimeFive Prime Therapeutics, Inc.
FTCFederal Trade Commission
GAAPU.S. generally accepted accounting principles
GensentaGensenta İlaç Sanayi ve Ticaret A.Ş.
HHSU.S. Department of Health & Human Services
IPR&Din-process research and development
IRAInflation Reduction Act of 2022
IRPinternational reference pricing
IRSInternal Revenue Service
KKCKyowa Kirin Co., Ltd.
LIBORLondon Interbank Offered Rate
MD&Amanagement’s discussion and analysis
MFNmost-favored nation
Moody’sMoody’s Investors Service, Inc.
NeumoraNeumora Therapeutics, Inc.
OECDOrganisation for Economic Co-operation and Development
PBMpharmacy benefit manager
PDABPrescription Drug Affordability Board
PTABPatent Trial and Appeal Board
R&Dresearch and development
RARRevenue Agent Report
ROWrest of world
S&PStandard & Poor’s Financial Services LLC
SECU.S. Securities and Exchange Commission
SG&Aselling, general and administrative
TeneobioTeneobio, Inc.
U.S. TreasuryU.S. Department of Treasury
USPTOU.S. Patent and Trademark Office
UTBunrecognized tax benefit
ii


Products
The brand names of our products, our delivery devices and certain of our product candidates and their associated generic names are given below.
TermDescription
Aimovig
Aimovig® (erenumab-aooe)
AMGEVITA
AMGEVITA (adalimumab)
Aranesp
Aranesp® (darbepoetin alfa)
AVSOLA
AVSOLA® (infliximab-axxq)
BLINCYTO
BLINCYTO® (blinatumomab)
Corlanor
Corlanor® (ivabradine)
ENBREL
Enbrel® (etanercept)
EPOGEN
EPOGEN® (epoetin alfa)
EVENITY
EVENITY® (romosozumab-aqqg)
IMLYGIC
IMLYGIC® (talimogene laherparepvec)
KANJINTI
KANJINTI® (trastuzumab-anns)
KYPROLIS
KYPROLIS® (carfilzomib)
LUMAKRAS/LUMYKRAS
LUMAKRAS® / LUMYKRAS (sotorasib)
MVASI
MVASI® (bevacizumab-awwb)
Neulasta
Neulasta® (pegfilgrastim)
NEUPOGEN
NEUPOGEN® (filgrastim)
Nplate
Nplate® (romiplostim)
Onpro
Onpro®
Otezla
Otezla® (apremilast)
Parsabiv
Parsabiv® (etelcalcetide)
Prolia
Prolia® (denosumab)
Repatha
Repatha® (evolocumab)
RIABNI
RIABNI® (rituximab-arrx)
Sensipar/Mimpara
Sensipar®/Mimpara (cinacalcet)
TEZSPIRE
TEZSPIRE® (tezepelumab-ekko)
Vectibix
Vectibix® (panitumumab)
XGEVA
XGEVA® (denosumab)

iii


PART I — FINANCIAL INFORMATION 

Item 1.FINANCIAL STATEMENTS
AMGEN INC.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(In millions, except per-share data)
(Unaudited)

 Three months ended
September 30,
Nine months ended
September 30,
 2022202120222021
Revenues:
Product sales$6,237 $6,320 $18,249 $18,026 
Other revenues415 386 1,235 1,107 
Total revenues6,652 6,706 19,484 19,133 
Operating expenses:
Cost of sales1,588 1,609 4,659 4,736 
Research and development1,112 1,422 3,110 3,471 
Acquired in-process research and development   1,505 
Selling, general and administrative1,287 1,305 3,842 3,943 
Other5 (8)537 143 
Total operating expenses3,992 4,328 12,148 13,798 
Operating income2,660 2,378 7,336 5,335 
Other income (expense):
Interest expense, net(368)(296)(991)(862)
Other income (expense), net100 73 (747)97 
Income before income taxes2,392 2,155 5,598 4,570 
Provision for income taxes249 271 662 576 
Net income$2,143 $1,884 $4,936 $3,994 
Earnings per share:
Basic$4.01 $3.32 $9.16 $6.98 
Diluted$3.98 $3.31 $9.11 $6.93 
Shares used in calculation of earnings per share:
Basic535 567 539 572 
Diluted538 570 542 576 

See accompanying notes.
1





AMGEN INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(In millions)
(Unaudited)

Three months ended
September 30,
Nine months ended
September 30,
 2022202120222021
Net income$2,143 $1,884 $4,936 $3,994 
Other comprehensive income, net of reclassification adjustments and taxes:
Foreign currency translation(109)(35)(225)(60)
Cash flow hedges138 99 378 241 
Losses on available-for-sale securities (1) (1)
Other(9)(3)(9)(3)
Other comprehensive income, net of reclassification adjustments and taxes20 60 144 177 
Comprehensive income$2,163 $1,944 $5,080 $4,171 

See accompanying notes.
2





AMGEN INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In millions, except per-share data)

September 30, 2022December 31, 2021
(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents$9,502 $7,989 
Marketable securities1,976 48 
Trade receivables, net5,326 4,895 
Inventories4,757 4,086 
Other current assets2,501 2,367 
Total current assets24,062 19,385 
Property, plant and equipment, net5,188 5,184 
Intangible assets, net13,266 15,182 
Goodwill14,845 14,890 
Other noncurrent assets6,339 6,524 
Total assets$63,700 $61,165 
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable$1,204 $1,366 
Accrued liabilities11,584 10,731 
Current portion of long-term debt1,543 87 
Total current liabilities14,331 12,184 
Long-term debt37,161 33,222 
Long-term tax liabilities5,680 6,594 
Other noncurrent liabilities2,875 2,465 
Contingencies and commitments
Stockholders’ equity:
Common stock and additional paid-in capital; $0.0001 par value; 2,750.0 shares authorized; outstanding—533.5 shares in 2022 and 558.3 shares in 2021
32,371 32,096 
Accumulated deficit(28,066)(24,600)
Accumulated other comprehensive loss(652)(796)
Total stockholders’ equity3,653 6,700 
Total liabilities and stockholders’ equity$63,700 $61,165 

See accompanying notes.
3





AMGEN INC.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(In millions, except per-share data)
(Unaudited)

Number
of shares
of common
stock
Common
stock and
additional
paid-in capital
Accumulated
deficit
Accumulated
other
comprehensive
loss
Total
Balance as of December 31, 2021
558.3 $32,096 $(24,600)$(796)$6,700 
Net income— — 1,476 — 1,476 
Other comprehensive income, net of taxes— — — 33 33 
Dividends declared on common stock ($1.94 per share)
— — (1,034)— (1,034)
Issuance of common stock in connection with the Company’s equity award programs
0.5 18 — — 18 
Stock-based compensation expense— 78 — — 78 
Tax impact related to employee stock-based compensation expense
— (45)— — (45)
Repurchases of common stock (Note 10)(24.6)(900)(5,410)— (6,310)
Balance as of March 31, 2022
534.2 31,247 (29,568)(763)916 
Net income— — 1,317 — 1,317 
Other comprehensive income, net of taxes— — — 91 91 
Issuance of common stock in connection with the Company’s equity award programs
0.7 45 — — 45 
Stock-based compensation expense— 120 — — 120 
Tax impact related to employee stock-based compensation expense
— (69)— — (69)
Other— — (1)— (1)
Balance as of June 30, 2022
534.9 31,343 (28,252)(672)2,419 
Net income— — 2,143 — 2,143 
Other comprehensive income, net of taxes— — — 20 20 
Dividends declared on common stock ($1.94 per share)
— — (1,057)— (1,057)
Issuance of common stock in connection with the Company’s equity award programs
0.1 15 — — 15 
Stock-based compensation expense— 121 — — 121 
Tax impact related to employee stock-based compensation expense
— (8)— — (8)
Repurchases of common stock (Note 10)(1.5)900 (900)—  
Balance as of September 30, 2022
533.5 $32,371 $(28,066)$(652)$3,653 

See accompanying notes.








4





AMGEN INC.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (continued)
(In millions, except per-share data)
(Unaudited)

Number
of shares
of common
stock
Common
stock and
additional
paid-in capital
Accumulated
deficit
Accumulated
other
comprehensive
loss
Total
Balance as of December 31, 2020
578.3 $31,802 $(21,408)$(985)$9,409 
Net income— — 1,646 — 1,646 
Other comprehensive income, net of taxes— — — 152 152 
Dividends declared on common stock ($1.76 per share)
— — (1,012)— (1,012)
Issuance of common stock in connection with the Company’s equity award programs
0.7 6 — — 6 
Stock-based compensation expense— 57 — — 57 
Tax impact related to employee stock-based compensation expense
— (59)— — (59)
Repurchases of common stock(3.7)— (865)— (865)
Balance as of March 31, 2021
575.3 31,806 (21,639)(833)9,334 
Net income— — 464 — 464 
Other comprehensive loss, net of taxes— — — (35)(35)
Issuance of common stock in connection with the Company’s equity award programs
0.8 47 — — 47 
Stock-based compensation expense— 100 — — 100 
Tax impact related to employee stock-based compensation expense
— (76)— — (76)
Repurchases of common stock(6.5)— (1,592)— (1,592)
Other— — 5 — 5 
Balance as of June 30, 2021
569.6 31,877 (22,762)(868)8,247 
Net income— — 1,884 — 1,884 
Other comprehensive income, net of taxes— — — 60 60 
Dividends declared on common stock ($1.76 per share)
— — (1,017)— (1,017)
Issuance of common stock in connection with the Company’s equity award programs
 9 — — 9 
Stock-based compensation expense— 111 — — 111 
Tax impact related to employee stock-based compensation expense
— (8)— — (8)
Repurchases of common stock(4.6)— (1,069)— (1,069)
Balance as of September 30, 2021
565.0 $31,989 $(22,964)$(808)$8,217 

See accompanying notes.

5





AMGEN INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In millions)
(Unaudited)

 Nine months ended
September 30,
 20222021
Cash flows from operating activities:
Net income$4,936 $3,994 
Depreciation, amortization and other2,506 2,546 
Deferred income taxes(847)(264)
Acquired in-process research and development 1,505 
Adjustments for equity method investments713 130 
Loss on divestiture565  
Other items, net236 57 
Changes in operating assets and liabilities, net of acquisitions:
Trade receivables, net(566)(269)
Inventories(651)(215)
Other assets166 (373)
Accounts payable(142)(260)
Accrued income taxes, net(492)(719)
Long-term tax liabilities185 102 
Other liabilities463 219 
Net cash provided by operating activities7,072 6,453 
Cash flows from investing activities:
Purchases of marketable securities(2,363)(8,901)
Proceeds from sales of marketable securities 4,403 
Proceeds from maturities of marketable securities447 7,927 
Purchases of property, plant and equipment(596)(593)
Cash paid for acquisitions, net of cash acquired (1,639)
Other(59)(234)
Net cash (used in) provided by investing activities(2,571)963 
Cash flows from financing activities:
Net proceeds from issuance of debt6,938 4,946 
Extinguishment of debt(297) 
Repurchases of common stock (Note 10)
(6,360)(3,532)
Dividends paid(3,156)(3,023)
Other(113)(104)
Net cash used in financing activities(2,988)(1,713)
Increase in cash and cash equivalents1,513 5,703 
Cash and cash equivalents at beginning of period7,989 6,266 
Cash and cash equivalents at end of period$9,502 $11,969 

See accompanying notes.
6





AMGEN INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2022
(Unaudited)

1. Summary of significant accounting policies
Business
Amgen Inc. (including its subsidiaries, referred to as “Amgen,” “the Company,” “we,” “our” or “us”) is a global biotechnology pioneer that discovers, develops, manufactures and delivers innovative human therapeutics. We operate in one business segment: human therapeutics.
Basis of presentation
The financial information for the three and nine months ended September 30, 2022 and 2021, is unaudited but includes all adjustments (consisting of only normal, recurring adjustments unless otherwise indicated), which Amgen considers necessary for a fair presentation of its condensed consolidated results of operations for those periods. Interim results are not necessarily indicative of results for the full fiscal year.
The condensed consolidated financial statements should be read in conjunction with our consolidated financial statements and the notes thereto contained in our Annual Report on Form 10-K for the year ended December 31, 2021, and with our condensed consolidated financial statements and the notes thereto contained in our Quarterly Reports on Form 10-Q for the periods ended March 31, 2022 and June 30, 2022.
Principles of consolidation
The condensed consolidated financial statements include the accounts of Amgen as well as its majority-owned subsidiaries. In determining whether we are the primary beneficiary of a variable interest entity, we consider whether we have both the power to direct activities of the entity that most significantly impact the entity’s economic performance and the obligation to absorb losses of or the right to receive benefits from the entity that could potentially be significant to that entity. We do not have any significant interests in any variable interest entities of which we are the primary beneficiary. All material intercompany transactions and balances have been eliminated in consolidation.
Use of estimates
The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results may differ from those estimates.
Property, plant and equipment, net
Property, plant and equipment is recorded at historical cost, net of accumulated depreciation and amortization, of $9.2 billion and $8.8 billion as of September 30, 2022 and December 31, 2021, respectively.
Recent accounting pronouncements
In March 2020, the FASB issued a new accounting standard to ease the financial reporting burdens caused by the expected market transition from LIBOR and other interbank offered rates to alternative reference rates, commonly referred to as reference rate reform. The new standard provides temporary optional expedients and exceptions to current GAAP guidance on contract modifications and hedge accounting. Specifically, a modification to transition to an alternative reference rate is treated as an event that does not require contract remeasurement or reassessment of a previous accounting treatment. Moreover, for all types of hedging relationships, an entity is permitted to change the reference rate without having to dedesignate the hedging relationship. The standard is generally effective for all contract modifications made and hedging relationships evaluated through December 31, 2022. In January 2021, the FASB issued a new accounting standard that expanded the scope of the original March 2020 standard to include derivative instruments on discounting transactions. We do not expect the two standards to have a material impact on our consolidated financial statements.
7





In November 2021, the FASB issued a new accounting standard around the recognition and measurement of contract assets and contract liabilities from revenue contracts with customers acquired in a business combination. The new standard clarifies that contract assets and contract liabilities acquired in a business combination from an acquiree should initially be recognized by applying revenue recognition principles and not at fair value. The standard is effective for interim and annual periods beginning on January 1, 2023, and early adoption is permitted. The impact of this standard will depend on the facts and circumstances of future transactions.

2. Acquisitions and divestitures
Acquisition of Teneobio, Inc.
On October 19, 2021, we acquired all of the outstanding stock of Teneobio, a privately held, clinical-stage biotechnology company developing a new class of biologics called human heavy-chain antibodies, which are single-chain antibodies composed of the human heavy-chain domain. The transaction, which was accounted for as a business combination, includes Teneobio’s proprietary bispecific and multispecific antibody technologies, which complement Amgen’s existing antibody capabilities and bispecific T-cell engager (BiTE®) platform and will enable significant acceleration and efficiency in the discovery and development of new molecules to treat diseases across Amgen’s core therapeutic areas. Upon its acquisition, Teneobio became a wholly owned subsidiary of Amgen, and its operations have been included in our condensed consolidated financial statements commencing on the acquisition date.
Measurement period adjustments for the nine months ended September 30, 2022, included changes to the purchase price allocation and total consideration, resulting in a net increase of $22 million to goodwill. The measurement period adjustments resulted primarily from valuation inputs pertaining to certain acquired assets based on facts and circumstances that existed as of the acquisition date and did not result from events subsequent to the acquisition date. These adjustments did not have a significant impact on Amgen’s results of operations during the nine months ended September 30, 2022, and would not have had a significant impact on prior-period results if these adjustments had been made as of the acquisition date. The following table summarizes the final total consideration and allocated acquisition date fair values of assets acquired and liabilities assumed, inclusive of measurement period adjustments (in millions):
Amounts
Cash purchase price$993 
Contingent consideration299 
Total consideration$1,292 
Cash and cash equivalents$100 
In-process research and development991 
Finite-lived intangible asset – research and development technology rights115 
Finite-lived intangible assets – licensing rights41 
Goodwill273 
Other assets, net16 
Deferred tax liability(244)
Total assets acquired, net$1,292 
Consideration for this transaction comprised of (i) an upfront cash payment of $993 million, which included a working-capital adjustment, and (ii) future contingent milestone payments to Teneobio’s former equity holders of up to $1.6 billion in cash, based on the achievement of various development and regulatory milestones with regard to the lead asset (AMG 340, formerly TNB-585) and to various development milestones for other drug candidates. The estimated fair values of the contingent consideration obligations aggregated $299 million as of the acquisition date and were determined using a probability-weighted expected return methodology. The assumptions in this method include the probability of achieving the milestones and the expected payment dates, with such amounts discounted to present value based on our pretax cost of debt. See Note 11, Fair value measurement, for information regarding the estimated fair value of these obligations as of September 30, 2022.
8





The estimated fair values of acquired IPR&D assets totaled $991 million, of which $784 million relates to AMG 340, that is in a Phase 1 clinical trial for the treatment of metastatic castration-resistant prostate cancer (mCRPC), and the balance relates to four separate preclinical oncology programs. The R&D technology rights of $115 million relate to Teneobio’s proprietary bispecific and multispecific antibody technologies; the amount is being amortized over 10 years by using the straight-line method. Teneobio has also licensed its technology and certain identified targets to various third parties, representing contractual agreements valued at $41 million. The estimated fair values for these intangible assets were determined using a multi-period excess earnings income approach that discounts expected future cash flows to present value by applying a discount rate that represents the estimated rate that market participants would use to value the intangible assets. The projected cash flows were based on certain assumptions attributable to the respective intangible asset, including estimates of future revenues and expenses, the time and resources needed to complete development and the probabilities of obtaining marketing approval from the FDA and other regulatory agencies.
A deferred tax liability of $244 million was recognized on temporary differences related to the book bases and tax bases of the acquired identifiable assets and assumed liabilities, primarily driven by the intangible assets acquired.
The excess of the acquisition date consideration over the fair values assigned to the assets acquired and the liabilities assumed of $273 million was recorded as goodwill, which is not deductible for tax purposes. The goodwill value represents expected synergies from both AMG 340 and the technologies acquired.
Acquisition of Five Prime Therapeutics, Inc.
On April 16, 2021, Amgen completed its acquisition of Five Prime for a total cash consideration of $1.6 billion, net of cash acquired. The purchase price was funded with cash on hand. This transaction was accounted for as an asset acquisition because substantially all the value of the assets acquired was concentrated in the intellectual property rights of bemarituzumab, a Phase 3 first-in-class program for gastric cancer. Five Prime’s operations have been included in our condensed consolidated financial statements commencing after the acquisition date.
We allocated the consideration to acquire Five Prime to: the bemarituzumab IPR&D program of $1.5 billion, which was expensed immediately in Acquired IPR&D expense in the Condensed Consolidated Statements of Income; deferred tax assets of $177 million; and other net liabilities of $47 million. The Acquired IPR&D expense was not tax deductible.
Divestiture of Gensenta İlaç Sanayi ve Ticaret A.Ş.
On June 28, 2022, we entered into a share purchase agreement with Eczacıbaşı under which Eczacıbaşı would acquire all of our shares in Gensenta, a subsidiary in Turkey, in exchange for $135 million in cash. Net assets related to Gensenta of $76 million met the criteria to be classified as held-for-sale and did not meet the criteria to be classified as discontinued operations. The transaction closed on November 2, 2022, upon satisfaction of closing conditions, including approval from the Turkish Competition Authority. See Note 14, Subsequent events.
As of September 30, 2022, held-for-sale assets and liabilities of $94 million and $18 million were included in Other current assets and Accrued liabilities, respectively, in the Condensed Consolidated Balance Sheets. During the nine months ended September 30, 2022, we recognized a loss of $565 million recorded in Other operating expenses in the Condensed Consolidated Statements of Income, primarily due to the impact of the cumulative foreign currency translation loss, with valuation allowances to Other current assets and Accrued liabilities in the Condensed Consolidated Balance Sheets.
9





3. Revenues
We operate in one business segment: human therapeutics. Therefore, results of our operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. Revenues by product and by geographic area, based on customers’ locations, are presented below. The majority of ROW revenues relates to products sold in Europe.
Revenues were as follows (in millions):
Three months ended September 30,
20222021
U.S.ROWTotalU.S.ROWTotal
ENBREL$1,086 $20 $1,106 $1,263 $26 $1,289 
Prolia590 272 862 530 273 803 
Otezla529 98 627 495 114 609 
XGEVA363 132 495 372 145 517 
Aranesp128 230 358 149 247 396 
Repatha142 167 309 139 133 272 
KYPROLIS217 101 318 198 95 293 
Neulasta205 42 247 360 55 415 
Nplate162 126 288 156 117 273 
Other products(1)
1,044 583 1,627 896 557 1,453 
Total product sales(2)
$4,466 $1,771 6,237 $4,558 $1,762 6,320 
Other revenues415 386 
Total revenues$